For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The closing price of NewAmsterdam Pharma Company NV (NASDAQ: NAMS) was $20.04 for the day, up 0.65% from the previous closing price of $19.91. In other words, the price has increased by $0.65 from its previous closing price. On the day, 0.51 million shares were traded.
Ratios:
Our analysis of NAMS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 10.61 and its Current Ratio is at 10.61. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $48.
On March 14, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $35.Scotiabank initiated its Sector Outperform rating on March 14, 2024, with a $35 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 27 ’25 when Douglas F Kling bought 500,000 shares for $23.20 per share.
Mayur Somalya bought 200,000 shares of NAMS for $4,640,000 on Jan 27 ’25. On Jan 10 ’25, another insider, NAP PoolCo B.V., who serves as the Affiliate of the company, bought 1,396,241 shares for $25.31 each.
Stock Price History:
Over the past 52 weeks, NAMS has reached a high of $27.29, while it has fallen to a 52-week low of $15.19. The 50-Day Moving Average of the stock is -13.33%, while the 200-Day Moving Average is calculated to be 0.82%.
Shares Statistics:
A total of 92.17M shares are outstanding, with a floating share count of 55.12M. Insiders hold about 48.41% of the company’s shares, while institutions hold 49.12% stake in the company.
Earnings Estimates
NewAmsterdam Pharma Company NV (NAMS) is presently subject to a detailed evaluation by 9 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.41, with high estimates of -$0.19 and low estimates of -$0.48.
Analysts are recommending an EPS of between -$1.73 and -$2.1 for the fiscal current year, implying an average EPS of -$1.98. EPS for the following year is -$1.74, with 9.0 analysts recommending between -$1.19 and -$2.18.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for NAMS’s current fiscal year. The highest revenue estimate was $36.86M, while the lowest revenue estimate was $13.42M, resulting in an average revenue estimate of $31.05M. In the same quarter a year ago, actual revenue was $13.01M
